Tango Therapeutics, Inc. reports developments as a clinical-stage biotechnology company focused on precision oncology. The company uses the genetic principle of synthetic lethality to discover and develop cancer therapies, with news centered on its PRMT5 inhibitor program, including vopimetostat, and related oncology combination research.
Recurring updates also cover financial results and business highlights, clinical supply and collaboration activity, investor-conference participation, board and executive appointments, and equity compensation actions under the company’s 2023 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
Tango Therapeutics has completed its business combination with BCTG Acquisition Corp., a special purpose acquisition company, with the combined company to be listed on the Nasdaq under the ticker TNGX. The transaction is expected to provide Tango with a substantial cash position of approximately $515 million, which includes $342 million in gross proceeds from the business combination. This funding will support Tango’s goal of developing precision oncology therapies, focusing on novel treatments for genetically-defined cancer patient populations.